In July Addenbrooke’s, part of Cambridge University Hospitals NHS Foundation Trust, began treating patients using a “Radixact radio therapy delivery system” to help those suffering from a wide variety of cancers including prostate, breast, neck and head.
Now Addenbrooke’s has a second Radixact system which is expected to go live in January. Specialist software means clinicians can adapt delivery to changes in tumour size, shape and location and the system is so precise some re-occurring cancers can be treated.
The identical systems mean the radiotherapy department, which sees more than 4,000 new patients a year from all over the region, can offer the treatment to even more.
The systems complement other high-tech equipment in the department, enabling clinicians to select the most suitable treatment for each patient.
CUH is an internationally renowned teaching hospital and a designated healthcare science centre. In addition to being the local hospital for Cambridgeshire, it is a regional centre for patients with rarer types of cancer.
Professional Head of Radiotherapy, Jemma Chapman, said: “Having a second Radixact System means that we are able to offer this treatment to more patients and ensure continuity of treatment.
“In combination with our other treatment machines, we are able to offer state-of-the art radiotherapy to a wide variety of patients from across the East of England.”
Image: Jemma Chapman and a new Radixact machine.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com